Abiomed (ABMD) Tops Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Piper Jaffray Raises Price Target as Abiomed's (ABMD) Results Fall In-line with Preliminary Release
February 5, 2016 9:02 AM ESTPiper Jaffray reiterated a Neutral rating on ABIOMED (NASDAQ: ABMD), and raised the price target to $90.00 (from $75.00), following the company's 3Q earnings report. Results included revenue of $85.8M, representing ~38% y/y growth. ABMD provided updated guidance and raised its FY16 expected revenues to at or slightly better than $326M up from... More
